Technical Analysis for CNTA - Centessa Pharmaceuticals plc

Grade Last Price % Change Price Change
A 19.03 6.67% 1.19
CNTA closed up 6.67 percent on Friday, February 7, 2025, on 2.43 times normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup 6.67%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Centessa Pharmaceuticals plc Description

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Pharmaceutical Solid Tumors Immunotherapy Drugs Non Small Cell Lung Cancer Orphan Drug Epidermal Growth Factor Receptor Idiopathic Pulmonary Fibrosis Lung Cancer Pulmonary Arterial Hypertension Lupus Oncogenes Hematological Malignancies Narcolepsy Alpha 1 Antitrypsin Hemophilia A Non Small Cell Lung Carcinoma Treatment Of Hemophilia Autosomal Dominant Polycystic Kidney Disease Cutaneous Squamous Cell Carcinoma Systemic Sclerosis

Is CNTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 19.09
52 Week Low 7.75
Average Volume 619,804
200-Day Moving Average 13.40
50-Day Moving Average 16.87
20-Day Moving Average 16.41
10-Day Moving Average 17.12
Average True Range 1.12
RSI (14) 67.85
ADX 14.86
+DI 23.78
-DI 15.44
Chandelier Exit (Long, 3 ATRs) 15.73
Chandelier Exit (Short, 3 ATRs) 17.80
Upper Bollinger Bands 18.42
Lower Bollinger Band 14.41
Percent B (%b) 1.15
BandWidth 24.44
MACD Line 0.34
MACD Signal Line 0.07
MACD Histogram 0.2671
Fundamentals Value
Market Cap 2.51 Billion
Num Shares 132 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -12.52
Price-to-Sales 366.12
Price-to-Book 5.03
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.10
Resistance 3 (R3) 20.89 19.99 20.75
Resistance 2 (R2) 19.99 19.46 20.09 20.64
Resistance 1 (R1) 19.51 19.14 19.75 19.72 20.52
Pivot Point 18.61 18.61 18.73 18.72 18.61
Support 1 (S1) 18.13 18.08 18.37 18.34 17.54
Support 2 (S2) 17.23 17.76 17.34 17.42
Support 3 (S3) 16.75 17.23 17.31
Support 4 (S4) 16.96